Paraneoplastic syndromes of the CNS.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18339348.
- Also identified by DOI 10.1016/S1474-4422(08)70060-7 and PMC identifier 2367117.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Major advances in the management of paraneoplastic neurologic disorders (PND) include the detection of new antineuronal antibodies, the improved characterisation of known syndromes, the discovery of new syndromes, and the use of CT and PET to reveal the associated tumours at an early stage. In addition, the definition of useful clinical criteria has facilitated the early recognition and treatment of these disorders. In this article, we review some classic concepts about PND and recent clinical and immunological developments, focusing on paraneoplastic cerebellar degeneration, opsoclonus-myoclonus, and encephalitides affecting the limbic system.
Medical subject headings
- Central Nervous System
- Paraneoplastic Syndromes, Nervous System